ABSTRACT
Preserving the quality of life and sexual function of patients with a localized prostate
cancer remains a challenge for physicians and a major issue for patients. The present
study aimed at demonstrating the feasibility of a dosimetric preservation of the sexual
organs during prostate stereotactic radiotherapy planning. Patients from a single
centre were retrospectively included in the RPAH-2 trial and randomized in Arm B if
they presented with either a low- or intermediate- risk prostate cancer. A 37.5Gy
in 5 fractions stereotactic body radiotherapy was delivered on the prostate gland.
The corpus cavernosum, penile bulb and internal pudental arteries were retrospectively
delineated before a re-optimization process. During this process, RPAH-2 trial dose
constraints were respected on Gross Tumor Volume (GTV), Planning Target Volume and
usual organs at risk. Pre-defined dose setting delivered to corpus cavernosum, penile
bulb and internal pudental arteries were collected and compared before and after the
re-optimization process. Nine patients were included in the study. A decrease of the
median of each investigated dose setting (except D90% for corpus cavernosum) was reported
after the re-optimization for corpus cavernosum, penile bulb and internal pudental
arteries. Our study demonstrated the feasibility of a dosimetric preservation of structures
considered as relevant to preserve sexual function after prostate stereotactic radiotherapy.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Medical DosimetryAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer—2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent.Eur Urol. 2021; 79: 243-262https://doi.org/10.1016/j.eururo.2020.09.042
- Influence of magnetic resonance imaging in the decision to preserve or resect neurovascular bundles at robotic assisted laparoscopic radical prostatectomy.J Urol. 2014; 192: 82-88https://doi.org/10.1016/j.juro.2014.01.005
- Intrafascial nerve-sparing radical prostatectomy improves patients’ postoperative continence recovery and erectile function: A pooled analysis based on available literatures.Medicine (Baltimore). 2018; 97: e11297https://doi.org/10.1097/MD.0000000000011297
- Robot-assisted laparoscopic prostatectomy versus open radical retropubic prostatectomy: 24-month outcomes from a randomised controlled study.Lancet Oncol. 2018; 19: 1051-1060https://doi.org/10.1016/S1470-2045(18)30357-7
- The hemodynamics of erectile dysfunction following external beam radiation for prostate cancer.J Sex Med. 2005; 2: 432-437https://doi.org/10.1111/j.1743-6109.2005.20362.x
- Vessel-sparing prostate radiotherapy: dose limitation to critical erectile vascular structures (internal pudendal artery and corpus cavernosum) defined by MRI.Int J Radiat Oncol Biol Phys. 2005; 61: 20-31https://doi.org/10.1016/j.ijrobp.2004.04.070
- Radiation-induced erectile dysfunction: recent advances and future directions.Adv Radiat Oncol. 2016; 1: 161-169https://doi.org/10.1016/j.adro.2016.05.003
- The natural history of erectile dysfunction after prostatic radiotherapy: a systematic review and meta-analysis.J Sex Med. 2017; 14: 1071-1078https://doi.org/10.1016/j.jsxm.2017.07.010
- Elucidating the etiology of erectile dysfunction after definitive therapy for prostatic cancer.Int J Radiat Oncol Biol Phys. 1998; 40: 129-133https://doi.org/10.1016/s0360-3016(97)00554-3
- Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial.Lancet. 2019; 394: 385-395https://doi.org/10.1016/S0140-6736(19)31131-6
- Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial.Lancet Oncol. 2019; 20: 1531-1543https://doi.org/10.1016/S1470-2045(19)30569-8
- Pelvic arterial hemorrhage in patients with pelvic fractures: detection with contrast-enhanced CT.Radiographics. 2004; 24 (discussion 1605-1606): 1591-1605https://doi.org/10.1148/rg.246045028
- Development and evaluation of an abridged, 5-item version of the International Index of Erectile Function (IIEF-5) as a diagnostic tool for erectile dysfunction.Int J Impot Res. 1999; 11: 319-326https://doi.org/10.1038/sj.ijir.3900472
- Erectile dysfunction after radiotherapy for prostate cancer and radiation dose to the penile structures: a critical review.Radiother Oncol. 2007; 84: 107-113https://doi.org/10.1016/j.radonc.2007.07.018
Article info
Publication history
Published online: June 10, 2022
Accepted:
May 5,
2022
Received in revised form:
April 15,
2022
Received:
July 5,
2021
Identification
Copyright
© 2022 American Association of Medical Dosimetrists. Published by Elsevier Inc. All rights reserved.
